Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 103 publications.

Garcia-Albeniz X, Stattin P, Westerberg M, Weinrib R, Sandstrom P, Vassilev Z. Design considerations for observational studies of drugs for advanced cancer. Pharmacoepidemiol Drug Saf. 2023 Mar 15. doi: 10.1002/pds.5612

Garcia de Albeniz Martinez X, Hampson L. Introduction to the ICH E9(R1) estimand and target trial emulation frameworks, and their role in the design and analysis of RWE studies. Presented at the ASA NJ Chapter Webinar Series; December 2, 2022.

Smith LH, Garcia-Albeniz X, Chan JM, Zhao S, Cowan JE, Broering JM, Cooperberg MR, Carroll PR, Hernan MA. Emulation of a target trial with sustained treatment strategies: an application to prostate cancer using both inverse probability weighting and the g-formula. Eur J Epidemiol. 2022 Dec 1;37(12):1205-13. doi: 10.1007/s10654-022-00929-7

Garcia de Albeniz Martinez X. Continuation of annual screening mammography and breast cancer mortality in women older than 70 years. Presented at the Vac4EU Virtual Journal Club; November 25, 2022.

Garcia de AlbenizMartinez X. Target trial emulation and pharmacovigilance. Presented at the North American Chapter of the International Society of Pharmacovigilance (NASoP); November 7, 2022.

Braitmaier M, Kollhorst B, Heinig M, Langner I, Czwikla J, Heinze F, Buschmann L, Minnerup H, Garcia-Albeniz X, Hense HW, Karch A, Zeeb H, Haug U, Didelez V. Effectiveness of mammography screening on breast cancer mortality - a study protocol for emulation of target trials using German health claims data. Clin Epidemiol. 2022 Nov 2;14:1293-303. doi: 10.2147/CLEP.S376107

Aparicio J, Virgili Manrique AC, Capdevila J, Munoz Boza F, Galvan P, Richart P, Oliveres H, Paez D, Hernando J, Serrano S, Vera R, Hernandez‑Yague X, Gallego RA, Riesco‑Martinez MC, Garcia de Albeniz Martinez X, Maurel J. Randomized phase II trial of FOLFIRI‑panitumumab compared with FOLFIRI alone in patients with RAS wild‑type circulating tumor DNA metastatic colorectal cancer beyond progression to first‑line FOLFOX‑panitumumab: the BEYOND study (GEMCAD 17‑01). Clin Trans Oncol. 2022 Nov;24(11):2155-65. doi: 10.1007/s12094-022-02868-x

Stattin P, Westerberg M, Franck Lissbrant I, Hjalm-Eriksson M, Kjellman A, Ullen A, Vassilev Z, Sandstrom P, Weinrib R, Martinez D, Garcia de Albeniz Martinez X. Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden. Clin Genitourin Cancer. 2022 Sep 9;S1558-7673(22):00194-X. doi: 10.1016/j.clgc.2022.09.002

Aguado J, Gutierrez L, Rothman KJ, Garcia de Albeniz X. Effect of different durations of treatment with antihypertensive drugs with anticholinergic effects on the risk of dementia: a target trial emulation study. Presented at the 2022 ICPE Conference; August 27, 2022. Copenhagen, Denmark.

Lund JL, Garcia de Albeniz X, Maringe C, Gaber C, Wyss R, Salas M, Ghazarian A. Cloning, censoring, and weighting – oh my! Applications of target trial emulation for evaluating cancer interventions when study eligibility, intervention initiation, and start of follow-up are not aligned. Presented at the 2022 ICPE Conference; August 27, 2022. Copenhagen, Denmark.

Bratton E, Izem R, Garcia de Albeniz X, Li J. Real-World Evidence (RWE) generation for rare disease drug development and orphan drug approvals. Presented at the 2022 ICPE Conference; August 25, 2022. Copenhagen, Denmark.

Garcia-Albeniz X, Del Amo J, Polo R, Morales-Asencio JM, Hernan MA. Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19. Eur J Epidemiol. 2022 Aug 9;37(8):789-96. doi: 10.1007/s10654-022-00891-4

Polo R, Garcia-Albeniz X, Teran C, Morales M, Rial-Crestelo D, Garcinuno MA, Garcia del Toro M, Hita C, Gomez-Sirvent JL, Buzon L, Diaz de Santiago A, Perez Arellano JL, Sanz J, Bachiller P, Martinez Alfaro E, Diaz-Brito V, Masia M, Hernandez-Torres A, Guerra J, Santos J, Arazo P, Munoz L, Arribas JR, Martinez de Salazar P, Moreno S, Hernan MA, Del Amo J. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers. Clin Microbiol Infect. 2022 Aug 5;1198-743X(22):00370-6. doi: 10.1016/j.cmi.2022.07.006.

Weibel D, Sturkenboom M, Eijkemans R, van den Bor R, Elbers R, Plana E, Garcia de Albeniz X, Weinrib R, Yefimenko N, Bianchini E, Stona L, Poblador-Plou B, Swart-Polinder K, Bartolini C, Hyeraci RG, Roy D, Lupattelli A, Villalobos F, Barbieri E, Garg RK, Rubino H, De Luise C, Arana A. VAC4EU active safety surveillance study of the BNT162b2 COVID-19 vaccine in five European countries: study design and first results. Presented at the 2022 ICPE Conference; August 2022. Copenhagen, Denmark.

Garcia de Albeniz X, Del Amo J, Polo R, Morales-Asencio JM, Hernan MA. Drug repurposing in a pandemic: systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19. What have we learned? Poster presented at the 2022 ICPE Conference; August 2022. Copenhagen, Denmark.

Garcia de Albeniz X, Polo R, Teran C, Morales M, Rial-Crestelo D, Garcinuno MA, Garcia del Toro M, Hita C, Gomez-Sirvent JL, Buzon L, Diaz de Santiago A, Perez JL, Sanz J, Bachiller P, Martinez E, Diaz-Brito V, Masia M, Hernandez-Torres A, Guerra J, Arazo P, Arribas J, Martinez de Salazar P, Moreno S, Hernan MA, Del Amo J. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers. A randomized clinical trial. Poster presented at the 2022 ICPE Conference; August 2022. Copenhagen, Denmark.

Forns J, Aguado J, Rivero-Ferrer E, Plana E, Dickerman BA, Garcia de Albeniz X. The effect of continuous use of antidepressants, with or without anticholinergic properties, for at least 4 months versus no treatment on the incidence of dementia: a target trial emulation. Poster presented at the 2022 ICPE Conference; August 2022. Copenhagen, Denmark.

Beau-Lejdstrom R, Hong LS, Garcia de Albeniz X, Floricel F, Lorenzen J, Bonfitto F, Kalilani L, Loesch C, Luscombe G, Perez-Gutthann S, Mottet I, Foskett N. Incidence of acute renal failure in patients using Levetiracetam versus other antiseizure medications: a voluntary post-authorization safety study. Drug Saf. 2022 Jul;45(7):781-90. doi: 10.1007/s40264-022-01193-0

Hong HL, Garcia de Albeniz X, Butler AMM, Whitaker H, Suchard MA. Methodological approaches to evaluating the safety and effectiveness of multi-dose coronavirus disease 2019 (COVID-19) vaccines series. Presented at the Virtual ICPE 2021 Conference; August 24, 2021.

Forns J, Aguado J, Rivero-Ferrer E, Plana E, Dickerman B, Garcia de Albaniz X. The effect of the anticholinergic properties of antidepressants on the incidence of dementia: a target trial emulation. Presented at the Virtual ICPE 2021 Conference; August 23, 2021.

Garcia de Albeniz Martinez X. How to study the effect of the duration of treatment using real-world data. A case study using breast cancer screening. Poster presented at the 2021 DIA Virtual Annual Meeting; June 27, 2021.

Garcia de Albeniz Martinez X. Causal inference methods for real world evidence: a case study of a target trial emulation. Presented at the 3rd Annual Real World Data, Life Science Analytics and Market Access Virtual Summit; October 23, 2020.

Dickerman BA, Garcia de Albeniz Martinez X, Logan RW, Denaxas S, Hernan MA. Emulating a target trial in case-control designs: an application to statins and colorectal cancer. Int J Epidemiol. 2020 Oct;49(5):1637-46. doi: 10.1093/ije/dyaa144

Gutierrez L, Danysh HE, Aguado J, Hunt PR, Kaye JA, Garcia-Albeniz X, Gilsenan A. Value of adding secondary read diagnosis codes to identify breast cancer and bladder cancer in the Clinical Practice Research Datalink: a pilot validation study. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Danysh HE, Gilsenan A, Beachler DC, Kaye JA, Garcia-Albeniz X, Schmid R, Hunter S, Hunt PR, Aguado J, Calingaert B, Layton JB, Gutierrez L. Validation of breast cancer and bladder cancer among patients with type 2 diabetes mellitus in Medicare: a pilot study. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Dinh J, Danysh HE, Johannes C, Gutierrez L, Schmid R, Arana A, Kaye JA, Pladevall-Vila M, Garcia de Albeniz X, Hunt PR, Gilsenan A, Beachler DC, Ke Zhou C. Description of acute kidney injury and breast cancer outcome validation processes across three databases. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Garcia de Albeniz X, Hsu J, Hernan MA. Causal estimands in survival analysis with competing events: an application to breast cancer screening. Presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Garcia de Albeniz X, Riera Guardia N, Gutierrez L, Bahmanyar S, Blin P, Droz C, Heinig M, Linder M, Moore N, Schulze-Rath R, Sultana J, Trifiro G, Zhang WW, Zong J. Feasibility of studying the use of tissue-agnostic cancer drugs in population-based European health databases. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Wu J, Pisa F, Izem R, Sultana J, Jones C, Garcia-Albeniz X, Bratton E. Real World Evidence (RWE) generation for rare diseases drug development: data sources and innovated methods. Presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 2020.

Petito LC, Garcia-Albeniz X, Logan RW, Howlader N, Mariotto AB, Dahabreh IJ, Hernan MA. Estimates of overall survival in patients with cancer receiving different treatment regimens: emulating hypothetical target trials in the Surveillance, Epidemiology, and End Results (SEER)–Medicare linked database. JAMA Netw Open. 2020 Mar 2;3(3):e200452. doi: 10.1001/jamanetworkopen.2020.0452

Garcia-Albeniz X, Hernan MA, Logan RW, Price M, Armstrong K, Hsu J. Continuation of annual screening mammography and breast cancer mortality in women older than 70 years. Ann Intern Med. 2020 Feb 25;172:381-9. doi: 10.7326/M18-1199

Garcia-Albeniz X, Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, Maurel J. Prospective biomarker study in advanced RAS wild‐type colorectal cancer: POSIBA Trial (GEMCAD 10‐02). Oncologist. 2019 Nov;24(11):e1115-22. doi: 10.1634/theoncologist.2018-0728

Garcia-Albeniz X, Hsu J, Bretthauer M, Hernan MA. Estimating the effect of preventive services with databases of administrative claims: reasons to be concerned. Am J Epidemiol. 2019 Oct;188(10):1764-7. doi: 10.1093/aje/kwz049

Dickerman BA, Garcia-Albeniz X, Logan RW, Denaxas S, Hernan MA. Avoidable flaws in observational analyses: an application to statins and cancer. Nat Med. 2019 Oct;25(10):1601-6. doi: 10.1038/s41591-019-0597-x

Garcia de Albeniz X, Hernan M, Logan R, Price M, Hsu J. Continuation of annual screening mammograms and breast-cancer mortality in women over 70. Poster presented at the ESMO 2019 Congress; September 27, 2019. Barcelona, Spain.

Fernandez-Martos C, Pericay C, Losa F, Garcia-Carbonero R, Layos L, Rodriguez-Salas N, Martin-Richard M, Alonso-Orduna V, Vera R, Gallegeo J, Capdevila J, Salud A, Nogue M, Maurel J, Guash I, Montagut C, Lopez C, Macias I, Jain RK, Garcia-Albeniz X. Effect of aflibercept plus modified FOLFOX6 induction chemotherapy before standard chemoradiotherapy and surgery in patients with high-risk rectal adenocarcinoma: the GEMCAD 1402 randomized clinical trial. JAMA Oncol. 2019 Aug 29;5(11):1566-73. doi: 10.1001/jamaoncol.2019.2294

Garcia-Albeniz X, Hsu J, Hernan MA. A challenge of real world data: How to assign individuals to a treatment strategy when their data are consistent with several treatment strategies at baseline. Presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):476. doi: 10.1002/pds.4864

Zhou CK, Dinh J, Danysh HE, Johannes C, Gutierrez L, Schmid R, Arana A, Kaye JA, Pladevall-Vila M, Garcia-Albeniz X, Gangemi K, Yin R, Ruzafa JC, Gilsenan A, Beachler DC. Validity of claims-based algorithms to identify acute kidney injury, acute liver injury, severe complications of urinary tract infections, breast cancer, and bladder cancer among patients with type 2 diabetes: a pilot study. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):317. doi: 10.1002/pds.4864

Song LD, Newhouse JP, Garcia-De-Albeniz X, Hsu J. Changes in screening colonoscopy following Medicare reimbursement and cost-sharing changes. Health Serv Res. 2019 Aug;54(4):839-50. doi: 10.1111/1475-6773.13150

Garcia de Albeniz X. How to analyze and interpret randomized clinical trials: intention-to-treat vs. per-protocol analysis. Presented at the Spanish Multidisciplinary Research Group on Digestive Cancers; April 4, 2019. Madrid, Spain.

Garcia de Albeniz X. Pros of the per-protocol analysis. When and why not to use an intention-to-treat analysis. Presented at the Spanish Multidisciplinary Research Group on Digestive Cancers; April 4, 2019. Madrid, Spain.

Osorio J, Jerico C, Miranda C, Garsot E, Luna A, Miro M, Santamaria M, Artigau E, Rodriguez-Santiago J, Castro S, Feliu J, Aldeano A, Olona C, Momblan D, Ruiz D, Galofre G, Pros I, Garcia-Albeniz X, Lozano M, Pera M. Perioperative transfusion management in gastric cancer surgery: analysis of the Spanish subset of the EURECCA oesophago-gastric cancer registry. Cir Esp. 2018 Nov;96(9):546-54. doi: 10.1016/j.ciresp.2018.03.010

Garcia-Albeniz X, Hsu J, Hernan MA. A word of caution: all-cause mortality and residual confounding in Medicare claims data. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):343. doi: 10.1002/pds.4629

Alonso V, Escudero P, Fernandez-Martos C, Salud A, Mendez M, Gallego J, Rodriguez JR, Martin-Richard M, Fernandez-Plana J, Manzano H, Mendez JC, Zanui M, Falco E, Gil-Raga M, Rojo F, Cuatrecasas M, Feliu J, Garcia-Albeniz X, Maurel J. Coexpression of p-IGF-1R and MMP-7 modulates panitumumab and cetuximab efficacy in RAS wild-type metastatic colorectal cancer patients. Neoplasia. 2018 Jul;20(7):678-86. doi: 10.1016/j.neo.2018.05.004

Jackson JW, Garcia-Albeniz X. Studying the effects of nonindicated medications on cancer: etiologic versus action-focused analysis of epidemiologic data. Cancer Epidemiol Biomarkers Prev. 2018 May;27(5):520-4. doi: 10.1158/1055-9965.EPI-17-0862

Emilsson L, Garcia-Albeniz X, Logan RW, Caniglia EC, Kalager M, Hernan MA. Examining bias in studies of statin treatment and survival in patients with cancer. JAMA Oncol. 2018 Jan 1;4(1):63-70. doi: 10.1001/jamaoncol.2017.2752

Fernandez-Martos C, Pericay C, Losa F, Garcia-Carbonero R, Layos L, Rodriguez Salas N, Martin M, Alonso V, Vera R, Gallego J, Capdevila J, Salud A, Nogue M, Maurel J, Guasch I, Montagut Viladot C, Lopez-Lopez C, Canas MA, Declara IM, Garcia-Albeniz X. Randomized phase II study comparing induction (I) mFOLFOX6 with or without aflibercept followed by chemoradiation (CRT) and total mesorectal excision (TME) in high risk-rectal cancer. GEMCAD 14-02 trial. Poster presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3, 2018. Chicago, IL. [abstract] J Clin Oncol. 2018; 36(2018):e3518.

Codony-Servat J, Cuatrecasas M, Asensio E, Montironi C, Martinez-Cardus A, Marin-Aguilera M, Horndler C, Martinez-Balibrea E, Rubini M, Jares P, Reig O, Victoria I, Gaba L, Martin-Richard M, Alonso V, Escudero P, Fernandez-Martos C, Feliu J, Mendez JC, Mendez M, Gallego J, Salud A, Rojo F, Castells A, Prat A, Rosell R, Garcia-Albeniz X, Camps J, Maurel J. Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. Br J Cancer. 2017 Dec 5;117(12):1777-86. doi: 10.1038/bjc.2017.279.

Garcia-Albeniz X. Modeling to study the best timing for salvage ADT after RT data and analysis issues. Presented at the 2017 CISNET Prostate Cancer Modelling Symposium; November 3, 2017. Rockville, MD.

Garcia-De-Albeniz X. Effectiveness of screening colonoscopy to prevent CRC among Medicare beneficiaries aged 70-79 years. Behind the scenes. Presented at the Massachusetts General Hospital Seminar; October 5, 2017. Boston, MA.